Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
November 20, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate...
Voyager Reports Third Quarter 2024 Financial and Operating Results
November 12, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data...
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
November 06, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company...
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
November 05, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
September 16, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint...
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
September 05, 2024 08:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment...
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
August 29, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company...
Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
August 07, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company...
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
August 06, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease - - Three CNS gene therapy programs on...